Medicenna Therapeutics (MDNA.F) Hisse Özeti

MDNA.F temel anali̇z
Kar Tanesi Skoru
Değerleme	0/6
Gelecekteki Büyüme	2/6
Geçmiş Performans	0/6
Finansal Sağlık	4/6
Temettüler	0/6

Ödüller

Gelirin yılda 62.77% oranında artması öngörülüyor

Kazançlar son 5 yılda yılda 3% oranında arttı

Risk Analizi

1 yıldan az nakit akışı var

Geliri 1 milyon ABD dolarından az ( CA$0 )

Şu anda kârlı değil ve önümüzdeki 3 yıl içinde kârlı hale gelmesi beklenmiyor

Anlamlı bir piyasa değeri yok ( $27M )

MDNA.F Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Medicenna Therapeutics Corp. Rakipler

Fiyat Geçmişi ve Performans

Hisse fiyatlarındaki yükseliş, düşüş ve değişimlerin özeti Medicenna Therapeutics
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	CA$0.32
52 Haftanın En Yüksek Seviyesi	CA$1.43
52 Haftanın En Düşük Seviyesi	CA$0.30
Beta	1.91
1 Aylık Değişim	-29.63%
3 Aylık Değişim	-50.63%
1 Yıllık Değişim	-57.03%
3 Yıllık Değişim	-47.17%
5 Yıllık Değişim	-91.00%
Halka arzdan bu yana değişim	-78.46%

Son Haberler & Güncellemeler

Recent updates

Seeking Alpha • Sep 30

Medicenna extends period to exercise certain warrants

Medicenna Therapeutics (NASDAQ:MDNA) received conditional approval from the TSX to extend the expiry date of the common share purchase warrants of the company originally issued on October 17, 2019. The warrants, of which 1,549,052 are available to be extended, are exercisable for common shares of the company at a price of $1.75/common share and are set to expire on October 17, 2022, will now expire on July 17, 2023, an extension of 9 months. All other terms of the warrants, including the exercise price, remain unchanged. There are 1,661,552 warrants remaining available for exercise including 112,500 warrants held directly or indirectly by insiders of the company which will not be extended.

Seeking Alpha • Sep 13

Medicenna, Merck enter clinical trial collaboration to evaluate combo cancer treatment

Medicenna Therapeutics (NASDAQ:MDNA) on Tuesday said it had entered into a clinical trial collaboration and supply agreement with Merck (NYSE:MRK) to evaluate its agonist in combination with cancer drug Keytruda in its ongoing phase 1/2 study named ABILITY. Medicenna's (MDNA) agonist, MDNA11, is being assessed in the early- to mid-stage trial as a monotherapy and in combination with MRK's Keytruda to treat patients with cancerous tumors. As per the clinical trial collaboration deal, MDNA will sponsor the study and MRK will supply Keytruda. "Although we believe that MDNA11 has great potential as a single agent, combining it with Keytruda may significantly enhance therapeutic benefit in different types of cancer, potentially maximizing the value of MDNA11," MDNA CEO Fahar Merchant said in a statement. MDNA stock +1.5% to $1.03 in afternoon trading.

Seeking Alpha • Aug 15

Medicenna Therapeutics GAAP EPS of -$0.07 in-line

Medicenna Therapeutics press release (NASDAQ:MDNA): Q1 GAAP EPS of -$0.07 in-line. Medicenna had cash, cash equivalents, and marketable securities of $19.3 million at June 30, 2022, compared to $20.5 million at March 31, 2022.

Seeking Alpha • Aug 08

Medicenna Therapeutics stock slides on launch of units offering

Medicenna Therapeutics (NASDAQ:MDNA) shares fell 6% in Monday's extended session after the immunotherapy company announced the launch of an underwritten public offering of units in the U.S. Each unit will be comprised of one common share and one warrant to purchase common shares. The offering is expected to be priced in the context of the market, with the final terms to be determined at the time of pricing. The company plans to use the net proceeds primarily to fund the clinical development of MDNA11, the pre-clinical development of a BiSKIT candidate, working capital and for general corporate purposes.

Hissedar Getirileri

	MDNA.F	US Biotechs	US Pazar
7D	-6.3%	2.9%	2.5%
1Y	-57.0%	33.0%	26.4%

Getiri vs. Endüstri: MDNA.F geçen yıl % 33 oranında getiri sağlayan US Biotechs sektörünün gerisinde kaldı.

Getiri vs Piyasa: MDNA.F geçen yıl % 26.4 oranında getiri sağlayan US Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is MDNA.F's price volatile compared to industry and market?
MDNA.F volatility
MDNA.F Average Weekly Movement	9.7%
Biotechs Industry Average Movement	10.8%
Market Average Movement	7.2%
10% most volatile stocks in US Market	16.5%
10% least volatile stocks in US Market	3.1%

İstikrarlı Hisse Senedi Fiyatı: MDNA.F son 3 ayda US piyasasına kıyasla önemli bir fiyat oynaklığı yaşamadı.

Zaman İçindeki Volatilite: MDNA.F 'nin haftalık oynaklığı ( 10% ) son bir yıldır istikrarlı seyretti.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
n/a	18	Fahar Merchant	www.medicenna.com

Bir immünoterapi şirketi olan Medicenna Therapeutics Corp. kanser ve diğer hastalıkların tedavisi için Superkine'lerin ve güçlendirilmiş Superkine'lerin geliştirilmesi ve ticarileştirilmesiyle ilgilenmektedir. Tekrarlayan glioblastoma ve beyin tümörlerinin tedavisi için bir interlökin-4 (IL-4) EC olan bizaxofusp'u (MDNA55) geliştirmektedir. Şirket ayrıca kanserle savaşmak için gereken bağışıklık hücrelerini aktive etmek ve çoğaltmak için IL-2'nin geliştirilmiş bir versiyonu olan MDNA11'i; multipl skleroz ve graft versus host hastalığı gibi otoimmün hastalıklar için bir IL-2 antagonisti olan MDNA209'u; kanser immünoterapilerini tedavi etmek için ikili bir IL-4/IL-13 antagonisti olan MDNA413'ü; çeşitli solid tümörler için maskelenmiş çift fonksiyonlu bir anti-PD1-IL2 Superkine olan MDNA113'ü ve çeşitli tümörler için bir IL-13 Superkine olan MDNA132'yi geliştirmektedir.

Medicenna Therapeutics Corp. Temel Bilgiler Özeti

Medicenna Therapeutics'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
MDNA.F temel i̇stati̇sti̇kler
Piyasa değeri	US$27.18m
Kazançlar(TTM)	-US$9.40m
Gelir(TTM)	n/a

0.0x

P/S Oranı

-2.8x

F/K Oranı

MDNA.F aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
MDNA.F gelir tablosu (TTM)
Gelir	CA$0
Gelir Maliyeti	CA$0
Brüt Kâr	CA$0
Diğer Giderler	CA$12.99m
Kazançlar	-CA$12.99m

Son Raporlanan Kazançlar

Dec 31, 2025

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-0.16
Brüt Marj	0.00%
Net Kâr Marjı	0.00%
Borç/Özkaynak Oranı	0%

MDNA.F uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2026/05/26 11:11
Gün Sonu Hisse Fiyatı	2026/05/26 00:00
Kazançlar	2025/12/31
Yıllık Kazançlar	2025/03/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Medicenna Therapeutics Corp. 4 Bu analistlerden 3, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Charles Zhu	Guggenheim Securities, LLC
Swayampakula Ramakanth	H.C. Wainwright & Co.
Dev Prasad	Lucid Capital Markets

Medicenna Therapeutics (MDNA.F) Hisse Özeti

Ödüller

Risk Analizi

Medicenna Therapeutics Corp. Rakipler

Allarity Therapeutics

Barinthus Biotherapeutics

ABVC BioPharma

NextCure

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Medicenna Therapeutics Corp. has filed a Follow-on Equity Offering.

Medicenna Therapeutics Corp Announces First Patient Dosed in Neo-Cyt Study of Mdna11 in Neoadjuvant Melanoma

Medicenna Therapeutics Corp Announces Presentation Of NEOCYT Trial At ASCO

Medicenna Therapeutics Corp Presents Positive Data Demonstrating Superior Safety and Efficacy Potential of Its First-In-Class Anti-Pd-1 X Il-2 Bifunctional Superkine Mdna113 At Aacr

Medicenna Therapeutics Corp. Appoints Nageatte Ibrahim as Chief Medical Officer

Medicenna Therapeutics Corp Presents Preclinical Data for Mdna113 Bifunctional Superkine

Recent updates

Medicenna Therapeutics Corp. has filed a Follow-on Equity Offering.

Medicenna Therapeutics Corp Announces First Patient Dosed in Neo-Cyt Study of Mdna11 in Neoadjuvant Melanoma

Medicenna Therapeutics Corp Announces Presentation Of NEOCYT Trial At ASCO

Medicenna Therapeutics Corp Presents Positive Data Demonstrating Superior Safety and Efficacy Potential of Its First-In-Class Anti-Pd-1 X Il-2 Bifunctional Superkine Mdna113 At Aacr

Medicenna Therapeutics Corp. Appoints Nageatte Ibrahim as Chief Medical Officer

Medicenna Therapeutics Corp Presents Preclinical Data for Mdna113 Bifunctional Superkine

Medicenna Therapeutics Corp. Announces Board Changes, Effective February 12, 2026

Medicenna Therapeutics Corp. Announces Key Program Updates and 2026 Outlook

Medicenna Therapeutics Corp. Updates MDNA11 Clinical Trial Results at the ESMO-IO Congress 2025, Further Bolstering its Anti-Tumor Activity in Advanced Solid Tumors

Medicenna and Fondazione Melanoma Onlus Collaborate to Advance MDNA11 Before First-Line Therapy in a Randomized Neoadjuvant Combination Trial, “NEO-CYT”, in High-Risk, Surgically Resectable Stage III Melanoma

Medicenna Therapeutics Corp. Announces John H. Sampson Not Standing for Re-Election

Medicenna Therapeutics Corp., Annual General Meeting, Sep 25, 2025

Medicenna Presents Compelling Results from the ABILITY-1 Clinical Trial at the 2025 AACR Annual Meeting

Medicenna Therapeutics Corp. Reports Mdna11's Compelling Anti-Cancer Activity Is Associated with Significant Expansion of 'Stem-Like' Cancer Fighting Immune Cells At the Inaugural Aacr-Oncology Conference and Provides Ability-Oncology Study Update

Medicenna Therapeutics Corp. Presents Preclinical Data on MDNA11 as First Step to Shrink Tumors Before Surgery and Prevent Metastasis at the 2024 San Antonio Breast Cancer Symposium

Medicenna Therapeutics Corp Provides Clinical Update and Announces First Complete Responder in MDNA11 and KEYTRUDA®? (pembrolizumab) Combination Dose Escalation Arm of the ABILITY-1 Study

Medicenna Therapeutics Corp. Announces Updated Clinical Data from the Ongoing Phase 1/2 ABILITY-1 Study to Be Presented at the 2024 Immunotherapy Bridge Conference

Medicenna Therapeutics Corp. Presents Preclinical Data on MDNA11 and Bizaxofusp at the 2024 Annual Meeting of the Society for Neuro-Oncology (SNO)

Medicenna Therapeutics Corp. Announces Positive Single-Agent Activity of MDNA11 from Dose Expansion Cohort and Encouraging Safety Profile in Combination with KEYTRUDA® (Pembrolizumab) at the 39th Annual Meeting of SITC

Medicenna Therapeutics Corp. Presents Preclinical Data from Its Anti-PD1-IL-2 BiSKIT and IL-2 Super Agonist Programs At the 39Th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Medicenna Presents Preclinical Results from Its IL-2 Super-Antagonist and Anti -PD1-IL-2 Biskit Programs At the Promise of Interleukin-2 Therapy Conference

Medicenna Therapeutics Corp. Appoints Mr. Karim Lalji as New Addition to its Board of Directors

Medicenna Therapeutics Corp., Annual General Meeting, Sep 26, 2024

Medicenna Therapeutics Corp. Announces Ema Approval of Its Clinical Trial Application to Expand Its Phase 1/2 Ability-1 Study to Europe

Medicenna Therapeutics Presents Positive Survival Data for Bizaxofusp in Phase 2B Study At Asco 2024

Medicenna Therapeutics Files Form 15

Medicenna Therapeutics Corp. announced that it has received CAD 20 million in funding from RA Capital Management, L.P.

Medicenna Therapeutics Corp. announced that it expects to receive CAD 20 million in funding from RA Capital Management, L.P.

Medicenna Therapeutics Corp. Presents Updated Results of Single Agent MDNA11 Anti-Tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study

Medicenna to Provide Clinical Update on the Mdna11 Ability-1 Trial At the Upcoming American Association for Cancer Research Annual Meeting

Medicenna Therapeutics Corp. Announces First Patient Dosed in ABILITY-1 Study of MDNA11 in Combination with Keytruda® (Pembrolizumab) in Patients with Advanced Solid Tumors

Medicenna Therapeutics Corp. Announces Initiation of Enrollment in Combination Arm of Phase 1/2 ABILITY Study Evaluating MDNA11 with Merck’s Pembrolizumab

Medicenna Therapeutics Corp. Announces A Poster Presentation and an Oral Summary Highlighting Long-term Follow-up Up Results from the Phase 2b Clinical Trial of Bizaxofusp

Medicenna Therapeutics Corp. to Present 4 Year Follow-Up Phase 2B Bizaxofusp Survival Data in Recurrent Glioblastoma At the Society for Neuro-Oncology 2023 Annual Meeting

Medicenna Therapeutics Corp. Promising Single-Agent Response and Durability of MDNA11 in the Phase 1/2 ABILITY Study During Dose Escalation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer

Medicenna Presents Preclinical Data on MDNA113, its Targeted Metalloprotease Activated SuperKine (T-MASK) at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Medicenna Therapeutics Corp.(NasdaqCM:MDNA) dropped from NASDAQ Composite Index

Medicenna Therapeutics Corp. Announces the Departure of Jeff Caravella as Chief Financial Officer

New major risk - Revenue and earnings growth

Medicenna Therapeutics Corp. Announces Dosing of the First Patient in the Phase 2 Monotherapy Dose Expansion Portion of the Phase 1/2 ABILITY

Medicenna Therapeutics Appoints Humphrey Gardner, as Chief Medical Officer

Medicenna Therapeutics Corp. Presents Preclinical MDNA223 BiSKIT Data at the AACR Special Conference on Tumor Immunology and Immunotherapy

Medicenna Therapeutics Corp. to Present at the AACR Special Conference Cancer Research: Tumor Immunology and Immunotherapy

Medicenna Therapeutics Corp. Announces the Appointment of Jeff Caravella as Chief Financial Officer

Medicenna Therapeutics Corp. Announces Departure of Elizabeth Williams as Chief Financial Officer

Medicenna Therapeutics Corp. Completes MDNA11 Dose Escalation and Commences Monotherapy Dose Expansion in the Phase 1/2 ABILITY Study

Medicenna Therapeutics Corp. Appoints Dr. Arash Yavari as Chair of Development Advisory Committee

Medicenna Therapeutics Corp., Annual General Meeting, Sep 28, 2023

Price target decreased by 8.9% to US$5.83

Medicenna Therapeutics Corp. to Report Q3, 2023 Results on Feb 07, 2023

High number of new and inexperienced directors

Lead Independent Director recently bought US$54k worth of stock

Medicenna extends period to exercise certain warrants

Medicenna, Merck enter clinical trial collaboration to evaluate combo cancer treatment

Price target decreased to US$7.00

Medicenna Therapeutics GAAP EPS of -$0.07 in-line

Medicenna Therapeutics stock slides on launch of units offering

No longer forecast to breakeven

Price target decreased to US$8.40

Price target increased to US$10.50

High number of new and inexperienced directors

Forecast to breakeven in 2025

Price target decreased to US$9.20